Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT-001 lingual application in obesity
NCT03490786Phase 1Completed
- Sponsor
- Gila Therapeutics
- Start
- Jul 2017
- Primary completion
- Aug 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of peptide YY 3-36 in obesity, sponsored by Gila Therapeutics. Primary endpoint: Demonstrate safe doses of PGT-001 for reduction of body weight at 2 weeks. Started Jul 2017; status: completed.
02
Drugs
peptide YY 3-36
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03490786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03490786.